Center for Alcohol and Addiction Studies, Department of Psychiatry and Human Behavior, Department of Behavioral and Social Sciences, 121 South Main Street, Brown University, Providence, RI 02919, USA; Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, NIAAA and NIDA, NIH, 10 Center Drive, Bethesda, MD 20892, USA.
Alcohol. 2018 Nov;72:3-8. doi: 10.1016/j.alcohol.2017.10.001. Epub 2017 Oct 13.
The corticotropin releasing factor (CRF) exerts its effects by acting on its receptors and on the binding protein (CRFBP). Extensive literature suggests a role of CRF in alcohol use disorder (AUD). Less is known about the specific role, if any, of CRFBP in AUD. In this review, we summarize recent interdisciplinary efforts toward identifying the contribution of CRFBP in mediating CRF activation. The role of CRFBP in alcohol-related behaviors has been evaluated with the ultimate goal of designing effective novel therapeutic strategies for AUD. A series of in vitro, in vivo, ex vivo, and genetic studies presented here provides initial evidence that CRFBP may possess both inhibitory and excitatory roles, and supports the original hypothesis that it represents a novel pharmacological target for the treatment of AUD. This report summarizes the proceedings of one of the talks at the Young Investigator Award symposium at the Alcoholism and Stress: A Framework for Future Treatment Strategies Conference, Volterra, Italy.
促肾上腺皮质释放因子 (CRF) 通过与其受体和结合蛋白 (CRFBP) 相互作用发挥作用。大量文献表明 CRF 在酒精使用障碍 (AUD) 中起作用。然而,CRFBP 在 AUD 中的具体作用(如果有的话)知之甚少。在这篇综述中,我们总结了最近在确定 CRFBP 在介导 CRF 激活中的贡献方面的跨学科努力。评估了 CRFBP 在与酒精相关的行为中的作用,最终目标是为 AUD 设计有效的新型治疗策略。这里介绍的一系列体外、体内、离体和遗传研究提供了初步证据,表明 CRFBP 可能具有抑制和兴奋作用,并支持其最初的假设,即它代表了 AUD 治疗的新型药理学靶点。本报告总结了在意大利沃尔泰拉举行的酒精与压力:未来治疗策略会议上的青年研究员奖专题讨论会的一次演讲的会议记录。